Skip to main content

Main navigation

  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Main navigation

  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Psychopharmacology

Medication in hand
Can Peripherally Restricted Anticholinergics Like Trospium Reduce Risks?

Welcome to Schizophrenia Knowledge Base

This website is intended for healthcare professionals in the United States.

Yes, I am a US healthcare professional
No, I am not a US healthcare professional
Medication
CME: Harnessing the Evolving Understanding of Schizophrenia to Address Treatment Challenges and Unmet Needs
Symptoms
Understanding the Cholinergic System
Elder Pt Confused by Medication
Assessing Anticholinergic Burden
Medication
Anticholinergic Misuse: Can These Medications Be Addictive?
Brain image
Can Anticholinergic Medications Make Movement Disorders Worse?
Brain image
What’s the Role of Amantadine in Anticholinergic Deprescription?
Muscarinic Agonism
CME: The Future of Schizophrenia Care: A Closer Look at the Role of Muscarinic Acetylcholine Receptor Activation
Synapse
CME: Emerging Therapeutic Targets for Schizophrenia: A Focus on Muscarinic Acetylcholine Receptor Activation
Medication in hand
Navigating the A to Z of Schizophrenia, Part 3: Novel Treatment Mechanisms
Muscarinic Agonism
CME: Great Debates: Exploring Muscarinic Agonists in Schizophrenia Treatment

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Next page Next ›
  • Last page Last »
© 2025 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use Cookie Policy